Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07874373 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Magnesium Supplementation for the Prevention of Cisplatin-Induced Nephrotoxicity

StatusCompleted
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This prospective, randomized, open-label study evaluated whether intravenous magnesium sulphate added to standard hydration could reduce cisplatin-associated renal toxicity in adult patients with solid tumors receiving weekly cisplatin-based chemoradiotherapy. Participants were assigned to standard hydration with intravenous saline and furosemide or to the same hydration protocol supplemented with 1 g of intravenous magnesium sulphate before cisplatin administration. The primary outcome was early renal toxicity assessed 48 hours after cisplatin administration. Secondary outcomes included renal dysfunction at one year, changes in urinary kidney injury biomarkers (KIM-1, NGAL, and suPAR), hematological toxicity, and treatment response
Trial Details
NCT Number NCT07874373
Lead Sponsor Grigore T. Popa University of Medicine and Pharmacy
Conditions
(from sponsor)		 Cisplatin-induced Nephrotoxicity
Enrollment 43 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov